pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1299 |
Genomic Coordinates | chr9: 40929010 - 40929092 |
Synonyms | MIRN1299, hsa-mir-1299, MIR1299 |
Description | Homo sapiens miR-1299 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1299 | ||||||||||||||||||
Sequence | 62| UUCUGGAAUUCUGUGUGAGGGA |83 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Illumina | ||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |
---|---|
Gene Symbol | UBBP4 |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | C8166 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462572. RNA binding protein: AGO2. Condition:C8166 NL4-3
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | Prostate Tissue | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRX1760631. RNA binding protein: AGO2. Condition:AGO-CLIP-22RV1_B
... - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.). |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al. - Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
|
CLIP-seq Support 1 for dataset GSM1462572 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | C8166 / C8166 NL4-3 |
Location of target site | ENST00000583708.1 | 3UTR | cugacuacaacauccag |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
75 hsa-miR-1299 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT079552 | VAMP3 | vesicle associated membrane protein 3 | 2 | 2 | ||||||||
MIRT154885 | GNAS | GNAS complex locus | 2 | 4 | ||||||||
MIRT275056 | SESN2 | sestrin 2 | 2 | 4 | ||||||||
MIRT303051 | B3GNT2 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 | 2 | 4 | ||||||||
MIRT319158 | CCDC71L | coiled-coil domain containing 71 like | 2 | 2 | ||||||||
MIRT339620 | TMPO | thymopoietin | 2 | 2 | ||||||||
MIRT441961 | BACE2 | beta-site APP-cleaving enzyme 2 | 2 | 2 | ||||||||
MIRT445113 | DCAF4 | DDB1 and CUL4 associated factor 4 | 2 | 2 | ||||||||
MIRT445290 | CD274 | CD274 molecule | 2 | 2 | ||||||||
MIRT446037 | HMCN1 | hemicentin 1 | 2 | 2 | ||||||||
MIRT446162 | C8A | complement C8 alpha chain | 2 | 2 | ||||||||
MIRT446175 | ZNF37A | zinc finger protein 37A | 2 | 4 | ||||||||
MIRT446414 | OCA2 | OCA2 melanosomal transmembrane protein | 2 | 2 | ||||||||
MIRT446884 | TRIM25 | tripartite motif containing 25 | 2 | 2 | ||||||||
MIRT449789 | C1orf109 | chromosome 1 open reading frame 109 | 2 | 2 | ||||||||
MIRT450026 | EHD3 | EH domain containing 3 | 2 | 2 | ||||||||
MIRT450367 | ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif 5 | 2 | 2 | ||||||||
MIRT479739 | CCND1 | cyclin D1 | 2 | 2 | ||||||||
MIRT484809 | ZNFX1 | zinc finger NFX1-type containing 1 | 2 | 2 | ||||||||
MIRT485892 | ZFP36 | ZFP36 ring finger protein | 2 | 2 | ||||||||
MIRT486036 | UBBP4 | ubiquitin B pseudogene 4 | 2 | 2 | ||||||||
MIRT488295 | DHCR24 | 24-dehydrocholesterol reductase | 2 | 2 | ||||||||
MIRT497377 | METTL8 | methyltransferase like 8 | 2 | 2 | ||||||||
MIRT508219 | ZNF850 | zinc finger protein 850 | 2 | 6 | ||||||||
MIRT510923 | PRRX1 | paired related homeobox 1 | 2 | 4 | ||||||||
MIRT512661 | STEAP3 | STEAP3 metalloreductase | 2 | 2 | ||||||||
MIRT520031 | YOD1 | YOD1 deubiquitinase | 2 | 6 | ||||||||
MIRT528490 | AGTR2 | angiotensin II receptor type 2 | 2 | 2 | ||||||||
MIRT530083 | PAGR1 | PAXIP1 associated glutamate rich protein 1 | 2 | 4 | ||||||||
MIRT531086 | CCDC140 | coiled-coil domain containing 140 | 2 | 2 | ||||||||
MIRT535363 | PEX5L | peroxisomal biogenesis factor 5 like | 2 | 2 | ||||||||
MIRT535595 | NUDT21 | nudix hydrolase 21 | 2 | 2 | ||||||||
MIRT538613 | CCT5 | chaperonin containing TCP1 subunit 5 | 2 | 4 | ||||||||
MIRT539002 | AVL9 | AVL9 cell migration associated | 2 | 2 | ||||||||
MIRT545918 | ZC3H4 | zinc finger CCCH-type containing 4 | 2 | 2 | ||||||||
MIRT548482 | EEF2 | eukaryotic translation elongation factor 2 | 2 | 2 | ||||||||
MIRT555088 | PURB | purine rich element binding protein B | 2 | 2 | ||||||||
MIRT561421 | TRIB3 | tribbles pseudokinase 3 | 2 | 2 | ||||||||
MIRT564965 | WTAP | WT1 associated protein | 2 | 2 | ||||||||
MIRT571686 | RPRD2 | regulation of nuclear pre-mRNA domain containing 2 | 2 | 2 | ||||||||
MIRT574656 | KLHL15 | kelch like family member 15 | 2 | 2 | ||||||||
MIRT610037 | CNOT6 | CCR4-NOT transcription complex subunit 6 | 2 | 6 | ||||||||
MIRT612436 | SMOC2 | SPARC related modular calcium binding 2 | 2 | 2 | ||||||||
MIRT614349 | LOH12CR1 | BLOC-1 related complex subunit 5 | 2 | 2 | ||||||||
MIRT615304 | CCDC158 | coiled-coil domain containing 158 | 2 | 2 | ||||||||
MIRT615771 | FSD2 | fibronectin type III and SPRY domain containing 2 | 2 | 2 | ||||||||
MIRT615889 | MT1A | metallothionein 1A | 2 | 2 | ||||||||
MIRT619147 | ZNF326 | zinc finger protein 326 | 2 | 2 | ||||||||
MIRT622042 | SSBP2 | single stranded DNA binding protein 2 | 2 | 2 | ||||||||
MIRT637385 | R3HDM2 | R3H domain containing 2 | 2 | 2 | ||||||||
MIRT640739 | EPB41 | erythrocyte membrane protein band 4.1 | 2 | 2 | ||||||||
MIRT644418 | PIGS | phosphatidylinositol glycan anchor biosynthesis class S | 2 | 2 | ||||||||
MIRT647638 | FAIM2 | Fas apoptotic inhibitory molecule 2 | 2 | 2 | ||||||||
MIRT654305 | RBMS3 | RNA binding motif single stranded interacting protein 3 | 2 | 2 | ||||||||
MIRT654367 | RBM23 | RNA binding motif protein 23 | 2 | 2 | ||||||||
MIRT655944 | NDST1 | N-deacetylase and N-sulfotransferase 1 | 2 | 2 | ||||||||
MIRT655990 | MYRF | myelin regulatory factor | 2 | 2 | ||||||||
MIRT659692 | CD226 | CD226 molecule | 2 | 2 | ||||||||
MIRT665868 | TIAF1 | TGFB1-induced anti-apoptotic factor 1 | 2 | 2 | ||||||||
MIRT667317 | MYO18A | myosin XVIIIA | 2 | 2 | ||||||||
MIRT684312 | GTF3C4 | general transcription factor IIIC subunit 4 | 2 | 2 | ||||||||
MIRT694138 | CYP27C1 | cytochrome P450 family 27 subfamily C member 1 | 2 | 2 | ||||||||
MIRT698529 | TFRC | transferrin receptor | 2 | 2 | ||||||||
MIRT698834 | SSR2 | signal sequence receptor subunit 2 | 2 | 2 | ||||||||
MIRT700657 | PPP1R11 | protein phosphatase 1 regulatory inhibitor subunit 11 | 2 | 2 | ||||||||
MIRT705377 | ATP1B3 | ATPase Na+/K+ transporting subunit beta 3 | 2 | 2 | ||||||||
MIRT707314 | TMEM184B | transmembrane protein 184B | 2 | 2 | ||||||||
MIRT709027 | KBTBD13 | kelch repeat and BTB domain containing 13 | 2 | 2 | ||||||||
MIRT716032 | TMPRSS4 | transmembrane protease, serine 4 | 2 | 2 | ||||||||
MIRT718228 | LCE1A | late cornified envelope 1A | 2 | 2 | ||||||||
MIRT718475 | TMEM151A | transmembrane protein 151A | 2 | 2 | ||||||||
MIRT722333 | BEND6 | BEN domain containing 6 | 2 | 2 | ||||||||
MIRT734096 | TUG1 | taurine up-regulated 1 (non-protein coding) | 3 | 0 | ||||||||
MIRT734099 | NOTCH3 | notch 3 | 3 | 0 | ||||||||
MIRT755871 | LIF | LIF, interleukin 6 family cytokine | 4 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|